The objective of this randomized phase II open label trial is to determine the anti-tumor
activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical
progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH
(luteinizing hormone-releasing hormone) agonists or surgical castration.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC